arrow
M

Michael E. Abram

clinical development
H指数:35
被引数:5,464

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Norovirus GII.4 serological repertoire in older adults after GII.4 ancestral variant vaccination: a post-hoc analysis of a randomised, double-blind, phase 2 trial

诺如病毒GII.4血清学谱在GII.4祖先变异株疫苗接种后的老年人中:一项随机、双盲、二期试验的事后分析

2026-05-150
OAAI
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials (Vol 14, 4347, 2023)
2024-04-080
OAAI
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

两项nirsevimab随机临床试验中婴儿RSV感染的分子和表型特征

2023-07-1922
OAAI
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
2023-07-0135
PRE
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
2022-03-09167
OAAI
Global molecular diversity of RSV - the INFORM RSV study
2020-06-2621
OAAI
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
2016-04-01150
PREAI